European Atherosclerosis Society

Bempedoic Acid Receives Highest ESC/EAS Guideline Recommendation for Cardiovascular Risk Reduction

- Bempedoic acid has received a Class I, Level A recommendation in the 2025 ESC/EAS Guidelines for Management of Dyslipidaemias, marking the strongest endorsement for a non-statin therapy. - The guidelines recommend bempedoic acid for patients unable to take statin therapy to lower LDL-C levels and reduce cardiovascular events, with additional consideration for high-risk patients on maximally tolerated statin therapy. - The updated European guidelines emphasize earlier, aggressive combination therapy approaches, supporting Esperion's development of oral triple combination lipid-lowering therapies in the U.S. - Esperion's CEO highlighted that this European recognition validates bempedoic acid's clinical benefit and is expected to inform upcoming U.S. cholesterol treatment guidelines.